December 30, 2024

Nutrafol Safety Signal Emerges in Case Study

A previously healthy 26-year-old developed severe liver injury after using Nutrafol, with a biopsy confirming marked necroinflammatory damage with complete resolution upon discontinuation.

Conexiant

December 27, 2024

11 Medical Breakthroughs This Year

Explore medical breakthroughs from 2024, including advancements in Parkinson’s therapy, ulcerative colitis treatments, and gene therapy for hereditary deafness.

Conexiant

December 23, 2024

FDA Green-Lights Second GLP-1 Generic Drug

The FDA has approved the first generic GLP-1 injection for type 2 diabetes management, maintaining the safety profile and emphasizing clinical monitoring requirements for adverse effects.

Conexiant

December 23, 2024

Colonoscopy Prep: 48 Risk Factors Found

Study of 358,257 patients reveals Medicaid insurance and psychiatric disease predict poor colonoscopy preparation more strongly than traditionally assumed factors such as age or timing.

Conexiant

December 19, 2024

FDA Redefines 'Healthy' Food Claims

The regulation requires qualifying foods to contain amounts from at least one food group or subgroup referenced in the Dietary Guidelines for Americans.

Conexiant

December 19, 2024

FDA Rejects New Bowel Disease Drug

The FDA declined to approve Zealand Pharma's bowel disease drug and sought an additional trial to confirm the drug's safety and efficacy, impacting thousands of adult patients in the United States.

Reuters

December 18, 2024

Physicians With Kids Face Large Pay Gaps

Physician compensation remains a central concern in health care, influenced by educational debt, specialty-specific variations, and evolving employer policies.

Conexiant

December 17, 2024

FDA Targets Unapproved GLP-1 Drug Sellers

The FDA has issued warning letters to companies for selling unapproved versions of popular diabetes and weight-loss drugs. The companies falsely labeled products for 'research use only' despite evidence showing they are intended for human use.

Reuters

December 17, 2024

Teva Sanofi Drug Hits IBD Trial Goals

"These unprecedented results show that duvakitug could represent the next frontier in treating ulcerative colitis and Crohn’s disease."

Reuters